Coronavirus Vaccine Update: Multiple Companies Rush to Find Cure

Strategic Insights -

Leading pharmaceutical companies, including AstraZeneca, Pfizer, and Moderna, are in a race to develop an effective vaccine against the novel coronavirus. Meanwhile, traditional Ayurvedic medicine companies like Patanjali are also claiming to have developed a cure for Covid-19. As the global pandemic continues to spread, the world waits with bated breath for a vaccine that can stop the spread of the virus. The total number of coronavirus cases has now crossed the 8-million mark worldwide.

The UK has begun trials of a new vaccine candidate developed by Imperial College London, with 300 healthy participants set to receive two doses of the vaccine. AstraZeneca has signed a contract with European governments to supply up to 400 million doses of the University of Oxford-developed vaccine. Johnson and Johnson expects to begin human trials for its experimental Covid-19 vaccine in July, with a possible emergency approval by early 2021. Moderna Inc's mRNA vaccine has shown promising results in mice, and its Phase III clinical trial is set to begin in the US.

Other companies, such as Sinovac Biotech and Pfizer-BNTECH, are also working on developing Covid-19 vaccines. Sinovac's CoronaVac vaccine has shown positive preliminary results in phase I and II clinical trials, with 143 volunteers in phase I and 600 volunteers in phase II. Pfizer is co-producing its vaccine with BNTECH and is testing four candidates to identify the most viable one. The Serum Institute of India has partnered with the University of Oxford to develop a safe and affordable vaccine, and expects to have doses available by October 2020.

Key Takeaways:

  • AstraZeneca has signed a contract with European governments to supply up to 400 million doses of the University of Oxford-developed vaccine.
  • Johnson and Johnson expects to begin human trials for its experimental Covid-19 vaccine in July, with a possible emergency approval by early 2021.
  • Moderna Inc's mRNA vaccine has shown promising results in mice, with its Phase III clinical trial set to begin in the US.
  • Sinovac Biotech's CoronaVac vaccine has shown positive preliminary results in phase I and II clinical trials, with 143 volunteers in phase I and 600 volunteers in phase II.
  • Pfizer-BNTECH is testing four vaccine candidates to identify the most viable one.
  • The Serum Institute of India expects to have doses of the University of Oxford-developed vaccine available by October 2020.
  • Patanjali, an Ayurvedic medicine company, claims to have developed a cure for Covid-19 within 5-14 days.
  • Acharya Balkrishna, CEO of Patanjali, stated that the company's treatment is not an immunity booster, but a cure for Covid-19.

Statistics:

  • The total number of coronavirus cases worldwide has now crossed the 8-million mark.
  • AstraZeneca has signed a contract with European governments to supply up to 400 million doses of the University of Oxford-developed vaccine.
  • Johnson and Johnson expects to begin human trials for its experimental Covid-19 vaccine in July, with a possible emergency approval by early 2021.
  • Moderna Inc's mRNA vaccine has shown promising results in mice, with its Phase III clinical trial set to begin in the US.
  • Sinovac Biotech's CoronaVac vaccine has shown positive preliminary results in phase I and II clinical trials, with 143 volunteers in phase I and 600 volunteers in phase II.
  • Pfizer-BNTECH is testing four vaccine candidates to identify the most viable one.
  • The Serum Institute of India expects to have doses of the University of Oxford-developed vaccine available by October 2020.

Sources:

  • The Times of Israel
  • Imperial College London
  • AstraZeneca Plc
  • Johnson and Johnson
  • Moderna Inc
  • Sinovac Biotech
  • Pfizer-BNTECH
  • Serum Institute of India
  • Patanjali
  • US Food and Drug Administration (FDA)
  • US National Institutes of Health (NIH)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • SyndiGate Media Inc.
  • Legal Monitor Worldwide